Core Laboratories N.V. Logo

Core Laboratories N.V.

0Q82.L

(0.0)
Stock Price

18,40 EUR

7.79% ROA

16.74% ROE

25.21x PER

Market Cap.

0,00 EUR

86.95% DER

0% Yield

7.34% NPM

Core Laboratories N.V. Stock Analysis

Core Laboratories N.V. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Core Laboratories N.V. Fundamental Stock Analysis
# Analysis Rating
1 ROE

Unidentified ROE

2 ROA

Unidentified ROA

3 PBV

Unidentified ROA

4 DER

Unidentified DER

5 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

6 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

7 Assets Growth

Company's revenue has stayed stagnant, showing no signs of improvement and making it a less favorable choice.

8 Graham Number

Unidentified Graham Number

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Core Laboratories N.V. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Core Laboratories N.V. Technical Stock Analysis
# Analysis Recommendation

Core Laboratories N.V. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Core Laboratories N.V. Revenue
Year Revenue Growth
2012 981.080.000
2013 1.073.508.000 8.61%
2014 1.085.222.000 1.08%
2015 797.520.000 -36.07%
2016 590.232.000 -35.12%
2017 647.819.000 8.89%
2018 700.846.000 7.57%
2019 668.210.000 -4.88%
2020 487.267.000 -37.13%
2021 470.252.000 -3.62%
2022 489.735.000 3.98%
2023 501.372.000 2.32%
2023 509.790.000 1.65%
2024 518.548.000 1.69%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Core Laboratories N.V. Research and Development Expenses
Year Research and Development Expenses Growth
2012 0
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Core Laboratories N.V. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 43.185.000
2013 51.988.000 16.93%
2014 45.655.000 -13.87%
2015 49.729.000 8.19%
2016 39.390.000 -26.25%
2017 47.737.000 17.49%
2018 62.910.000 24.12%
2019 48.023.000 -31%
2020 34.033.000 -41.11%
2021 44.173.000 22.96%
2022 38.117.000 -15.89%
2023 45.808.000 16.79%
2023 40.259.000 -13.78%
2024 47.156.000 14.63%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Core Laboratories N.V. EBITDA
Year EBITDA Growth
2012 316.543.000
2013 359.756.000 12.01%
2014 375.634.000 4.23%
2015 215.087.000 -74.64%
2016 114.391.000 -88.03%
2017 135.910.000 15.83%
2018 142.942.000 4.92%
2019 124.624.000 -14.7%
2020 70.494.000 -76.79%
2021 59.813.000 -17.86%
2022 60.215.000 0.67%
2023 70.864.000 15.03%
2023 72.146.000 1.78%
2024 55.012.000 -31.15%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Core Laboratories N.V. Gross Profit
Year Gross Profit Growth
2012 359.261.000
2013 410.540.000 12.49%
2014 419.951.000 2.24%
2015 264.868.000 -58.55%
2016 152.729.000 -73.42%
2017 182.861.000 16.48%
2018 203.882.000 10.31%
2019 172.631.000 -18.1%
2020 102.125.000 -69.04%
2021 102.356.000 0.23%
2022 96.080.000 -6.53%
2023 114.904.000 16.38%
2023 109.833.000 -4.62%
2024 100.196.000 -9.62%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Core Laboratories N.V. Net Profit
Year Net Profit Growth
2012 216.071.000
2013 242.811.000 11.01%
2014 257.485.000 5.7%
2015 114.847.000 -124.2%
2016 65.060.000 -76.52%
2017 81.014.000 19.69%
2018 79.584.000 -1.8%
2019 94.150.000 15.47%
2020 -97.213.000 196.85%
2021 19.727.000 592.79%
2022 19.453.000 -1.41%
2023 37.028.000 47.46%
2023 36.675.000 -0.96%
2024 12.880.000 -184.74%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Core Laboratories N.V. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 5
2013 5 20%
2014 6 0%
2015 3 -150%
2016 1 -100%
2017 2 0%
2018 2 0%
2019 2 50%
2020 -2 200%
2021 0 0%
2022 0 0%
2023 1 0%
2023 1 0%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Core Laboratories N.V. Free Cashflow
Year Free Cashflow Growth
2012 206.051.000
2013 262.721.000 21.57%
2014 266.863.000 1.55%
2015 196.303.000 -35.94%
2016 120.531.000 -62.87%
2017 105.496.000 -14.25%
2018 90.086.000 -17.11%
2019 67.258.000 -33.94%
2020 45.988.000 -46.25%
2021 23.040.000 -99.6%
2022 14.740.000 -56.31%
2023 -3.673.000 501.31%
2023 14.210.000 125.85%
2024 2.478.000 -473.45%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Core Laboratories N.V. Operating Cashflow
Year Operating Cashflow Growth
2012 237.202.000
2013 298.137.000 20.44%
2014 303.449.000 1.75%
2015 219.100.000 -38.5%
2016 131.887.000 -66.13%
2017 124.271.000 -6.13%
2018 111.827.000 -11.13%
2019 89.527.000 -24.91%
2020 57.868.000 -54.71%
2021 36.579.000 -58.2%
2022 24.956.000 -46.57%
2023 -212.000 11871.7%
2023 24.789.000 100.86%
2024 5.530.000 -348.26%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Core Laboratories N.V. Capital Expenditure
Year Capital Expenditure Growth
2012 31.151.000
2013 35.416.000 12.04%
2014 36.586.000 3.2%
2015 22.797.000 -60.49%
2016 11.356.000 -100.75%
2017 18.775.000 39.52%
2018 21.741.000 13.64%
2019 22.269.000 2.37%
2020 11.880.000 -87.45%
2021 13.539.000 12.25%
2022 10.216.000 -32.53%
2023 3.461.000 -195.17%
2023 10.579.000 67.28%
2024 3.052.000 -246.63%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Core Laboratories N.V. Equity
Year Equity Growth
2012 187.913.000
2013 169.389.000 -10.94%
2014 93.993.000 -80.21%
2015 -23.699.000 496.61%
2016 155.296.999 115.26%
2017 148.732.000 -4.41%
2018 160.900.000 7.56%
2019 182.139.999 11.66%
2020 75.572.998 -141.01%
2021 161.001.000 53.06%
2022 188.954.000 14.79%
2023 229.807.000 17.78%
2023 229.450.000 -0.16%
2024 237.417.000 3.36%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Core Laboratories N.V. Assets
Year Assets Growth
2012 636.516.000
2013 661.010.000 3.71%
2014 673.325.000 1.83%
2015 625.258.000 -7.69%
2016 573.052.000 -9.11%
2017 584.812.000 2.01%
2018 648.827.000 9.87%
2019 774.673.000 16.25%
2020 568.579.000 -36.25%
2021 580.853.000 2.11%
2022 578.354.000 -0.43%
2023 586.395.000 1.37%
2023 592.414.000 1.02%
2024 587.950.000 -0.76%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Core Laboratories N.V. Liabilities
Year Liabilities Growth
2012 448.603.000
2013 491.621.000 8.75%
2014 579.332.000 15.14%
2015 648.957.000 10.73%
2016 417.755.000 -55.34%
2017 436.080.000 4.2%
2018 487.927.000 10.63%
2019 592.533.000 17.65%
2020 493.006.000 -20.19%
2021 419.852.000 -17.42%
2022 389.400.000 -7.82%
2023 356.588.000 -9.2%
2023 362.964.000 1.76%
2024 350.533.000 -3.55%

Core Laboratories N.V. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
10.91
Net Income per Share
0.8
Price to Earning Ratio
25.21x
Price To Sales Ratio
0x
POCF Ratio
28.24
PFCF Ratio
0
Price to Book Ratio
4.07
EV to Sales
0.37
EV Over EBITDA
2.51
EV to Operating CashFlow
5.58
EV to FreeCashFlow
8.47
Earnings Yield
0.04
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
0,19 Bil.
Graham Number
9.45
Graham NetNet
-4.57

Income Statement Metrics

Net Income per Share
0.8
Income Quality
0.89
ROE
0.17
Return On Assets
0.06
Return On Capital Employed
0.12
Net Income per EBT
0.87
EBT Per Ebit
0.73
Ebit per Revenue
0.12
Effective Tax Rate
0.46

Margins

Sales, General, & Administrative to Revenue
0.07
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.21
Operating Profit Margin
0.12
Pretax Profit Margin
0.08
Net Profit Margin
0.07

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0.05
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0.71
Free CashFlow per Share
0.47
Capex to Operating CashFlow
-0.34
Capex to Revenue
-0.02
Capex to Depreciation
-0.73
Return on Invested Capital
0.07
Return on Tangible Assets
0.08
Days Sales Outstanding
82.2
Days Payables Outstanding
29.42
Days of Inventory on Hand
64.04
Receivables Turnover
4.44
Payables Turnover
12.41
Inventory Turnover
5.7
Capex per Share
-0.24

Balance Sheet

Cash per Share
0,32
Book Value per Share
4,95
Tangible Book Value per Share
2.8
Shareholders Equity per Share
4.95
Interest Debt per Share
4.31
Debt to Equity
0.87
Debt to Assets
0.34
Net Debt to EBITDA
2.51
Current Ratio
2.68
Tangible Asset Value
0,13 Bil.
Net Current Asset Value
-0,12 Bil.
Invested Capital
0.87
Working Capital
0,14 Bil.
Intangibles to Total Assets
0.18
Average Receivables
0,11 Bil.
Average Payables
0,03 Bil.
Average Inventory
71206500
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Core Laboratories N.V. Dividends
Year Dividends Growth
2018 2
2019 2 0%
2020 0 0%
2022 0 0%

Core Laboratories N.V. Profile

About Core Laboratories N.V.

Core Laboratories N.V. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, Canada, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock, reservoir fluid, and gas samples to enhance production and improve recovery of oil and gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, and production. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. In addition, the company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. It operates approximately in 50 countries. The company was founded in 1936 and is based in Amstelveen, the Netherlands.

CEO
Mr. Lawrence V. Bruno
Employee
3.600
Address
Van Heuven Goedhartlaan 7 B
Amstelveen, 1181 LE

Core Laboratories N.V. Executives & BODs

Core Laboratories N.V. Executives & BODs
# Name Age
1 Mr. Kevin G. Daniels
Chief Accounting Officer, Treasurer & Vice President
70
2 J. Donald Dumas Jr.
Senior Vice President of Production Enhancement & Bus. Devel.
70
3 Mr. Jacobus Schouten
Managing Director
70
4 Mr. Lawrence V. Bruno
Chairman, Chief Executive Officer, Pres & Chief Operating Officer
70
5 Mr. Christopher Scott Hill
Senior Vice President & Chief Financial Officer
70
6 Mr. Mark Damian Tattoli
Senior Vice President, Sec. & Gen. Counsel
70
7 Ms. Gwendolyn Y. Gresham M.B.A.
Senior Vice President of Corporation Devel. & Investor Relations
70

Core Laboratories N.V. Competitors